Precedents Library
The precedents library contains curated regulatory text extracted from approved labels, public assessment reports, and authority decisions. These precedents are used to inform labeling language, variation justifications, and response strategies. AI agents can search this library in real time.
| ID | Product/Source | Authority | Type | Section | Relevance | Date | Excerpt |
|---|---|---|---|---|---|---|---|
| PRE-001 | Competitor Biologic A | EMA | SmPC | 4.1 | 95% | 2024-02-15 | "Treatment indicated in adults with moderate-to-severe disease after inadequate response to conventio…" |
| PRE-002 | Innovator Reference B | FDA | Label | Indications | 88% | 2023-11-08 | "For the treatment of HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.…" |
| PRE-003 | Biosimilar C | EMA | EPAR | Scientific Discussion | 82% | 2023-09-21 | "Comparative PK study demonstrated bioequivalence within the 80–125% acceptance criteria.…" |
| PRE-004 | Small Molecule D | PMDA | Review Report | PK section | 79% | 2024-04-10 | "No dose adjustment required in patients with renal impairment based on population PK analysis.…" |
| PRE-005 | Oncology Product E | FDA | Accelerated Approval | INDICATIONS | 91% | 2022-08-30 | "Accelerated approval based on overall response rate; full approval contingent on confirmatory trial.…" |
| PRE-006 | Rare Disease Treatment F | EMA | Orphan Designation | Condition | 85% | 2021-03-22 | "Orphan designation granted for prevalence less than 5 in 10,000 persons in the EU.…" |